Bolstering Interdepartmental Collaboration With a Unified Cancer Database

Commentary
Video

An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.

A novel comprehensive cancer database may help different aspects of cancer management, including assistance from a clinical assistance standpoint and the streamlining of ongoing research, according to Leila Tchelebi, MD.

In a conversation with CancerNetwork® regarding research that she and colleagues presented at the 2025 American Society for Radiation Oncology Annual Meeting, Tchelebi, a radiation oncologist at Northwell Health, described how a consolidated cancer database across a 14-institution system may bolster the multidisciplinary care of patients with cancer. She noted that the database stores all critical information related to a patient’s cancer stage, prior treatment, and survival outcomes in a single place, which can help inform clinical decision-making. Additionally, the information can be easily exported to other formats, making it easier to conduct clinical studies encompassing data on thousands of patient cases.

Transcript:

The beauty about this is that it helps with multiple different aspects of healthcare. From a clinical standpoint, physicians across different sites within the Health Network— not only within the health system, but [even] outside the system—if these data are shared, [they] can retrieve all the relevant information regarding a patient for ease of decision-making clinically. I am able to look at my patient and see what chemotherapy they have received already, what radiation therapy they might have received at another facility that might not have the same EMR; perhaps it was an inpatient facility, and I am working at an outpatient site. Clinically, it has been [quite] helpful for the cancer registry that is required, as I mentioned previously, to collect these data and submit them to the state. All the information regarding the patient’s cancer stage, treatments rendered, and survival outcomes can be accessed in 1 place.

Then, for research, if we are looking to do a quality assurance project across the network [and] see how many patients perhaps did not complete therapy, we can have all the relevant clinical information in 1 easy-to-access database. Then, all that information can be exported to something like an Excel spreadsheet, which can then be utilized to much more easily conduct clinical studies where thousands of patient cases can be imported into the spreadsheet, having collected data from across multiple different EMRs, all in 1 place. [This] makes the data much more easily synthesized and analyzed.

Reference

Tchelebi L, Lindsay WD, Yee K, Wishinsky J, Labarca ME, Potters L. Building a comprehensive cancer database across fourteen treatment facilities in a large health care system. Presented at: 2025 American Society for Radiation Oncology Annual Meeting; September 27-October 1, 2025; San Francisco, CA.

Recent Videos
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.